Are Sigma shares all hype and should be sold?
The full-year result (FY26) for Sigma Healthcare (ASX:SIG) highlighted progress on several key strategic initiatives, including i) The domestic store rollout, ii) Growth in the International business and ii) Further progression of the private label strategy. Notwithstanding upbeat Company commentary on the outlook for FY27, there are several factors presently weighing on sentiment. These include the slowdown in sales momentum from the flagship Chemist Warehouse (CW) network in Australia, lower-than-expected operating leverage despite strong sales performance), as well as a …
